Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have received a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $55.00.

Several research analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research note on Wednesday, June 17th. Cantor Fitzgerald initiated coverage on Silence Therapeutics in a research note on Wednesday, June 24th. They set an “overweight” rating for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Silence Therapeutics in a report on Tuesday, April 21st.

Institutional Trading of Silence Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of SLN. EHP Funds Inc. bought a new stake in shares of Silence Therapeutics during the 3rd quarter valued at $55,000. XTX Topco Ltd bought a new stake in Silence Therapeutics during the fourth quarter valued at about $71,000. China Universal Asset Management Co. Ltd. raised its holdings in Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after acquiring an additional 5,421 shares during the period. Citadel Advisors LLC purchased a new position in shares of Silence Therapeutics in the third quarter valued at about $112,000. Finally, Massar Capital Management LP purchased a new position in shares of Silence Therapeutics in the second quarter valued at about $115,000. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Price Performance

NASDAQ:SLN opened at $10.50 on Friday. The firm has a market capitalization of $495.97 million, a price-to-earnings ratio of -6.60 and a beta of 1.38. Silence Therapeutics has a one year low of $4.19 and a one year high of $11.19. The business has a fifty day moving average price of $7.89 and a 200-day moving average price of $6.59.

Silence Therapeutics (NASDAQ:SLN) last announced its earnings results on Friday, May 8th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The company had revenue of $0.42 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities research analysts expect that Silence Therapeutics will post -0.83 earnings per share for the current fiscal year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.